Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis

Página do item simplificado Estatísticas
dc.contributor.authorAraújo, Aurigena Antunes
dc.contributor.authorSouza, Graziene Lopes de
dc.contributor.authorSouza, Tatiana Oliveira
dc.contributor.authorBrito, Gerly Anne de Castro
dc.contributor.authorAragão, Karoline Sabóia
dc.contributor.authorMedeiros, Caroline Addison Xavier de
dc.contributor.authorLourenço, Yriu
dc.contributor.authorAlves, Maria do Socorro Costa Feitosa
dc.contributor.authorAraújo Jr, Raimundo Fernandes de
dc.date.accessioned2018-06-16T11:36:45Z
dc.date.available2018-06-16T11:36:45Z
dc.date.issued2013-06-19
dc.description.resumoThe objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway in the response to treatment with olmesartan, an angiotensin II type 1 receptor blocker. Male Wistar albino rats were randomly divided into five groups of ten rats each: (1) non-ligature with water, (2) ligature with water, (3) ligature with 1 mg/kg olmesartan, (4) ligature with 6 mg/kg olmesartan, and (5) ligature with 10 mg/kg olmesartan. All groups were treated with olmesartan or the vehicle by gavage daily for 10 days. Following the treatment course, the periodontal tissue of the animals was analyzed by histopathology and immunohistochemistry to determine the expression of cyclooxygenase-2 (COX-2), MMP-2, MMP-9, and members of the RANKL/RANK/OPG pathway and by ELISA and spectroscopic assay to determine the levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, myeloperoxidase (MPO), malonaldehyde (MDA), and glutathione. The concentrations of MPO and MDA were reduced in the group that received 6 mg/kg olmesartan (p < 0.05). In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1β (p < 0.05), and all doses of olmesartan resulted in decreased levels of TNF-α. Furthermore, treatment with 6 mg/kg olmesartan led to downregulation of the expression of COX-2, MMP-2, MMP-9, RANKL, and RANK and to upregulation of the expression of OPG. These findings suggest that 6 mg/kg olmesartan reduces the inflammatory process and bone loss by downregulating MMPs and RANKL in osteoblasts and by upregulating OPG.pt_BR
dc.identifier.citationARAÚJO, Aurigena Antunes de et al. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn-Schmiedeberg's Archives of Pharmacology, p. 875-84, 2013. Disponível em: <https://link.springer.com/article/10.1007/s00210-013-0886-8>. Acesso em: 14 mar. 2018.pt_BR
dc.identifier.doihttps://doi.org/10.1007/s00210-013-0886-8
dc.identifier.issn1432-1912
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/25416
dc.languageporpt_BR
dc.publisherSpringer-Verlag Berlin Heidelbergpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectExperimental periodontal diseasept_BR
dc.subjectCitocinespt_BR
dc.subjectImmunohistochemicalpt_BR
dc.subjectLipid peroxidantpt_BR
dc.subjectOlmesartanpt_BR
dc.titleOlmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitispt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
OlmesartanDecreases_Araujo_2013.pdf
Tamanho:
697.73 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar

Coleções

CB - DBF - Artigos publicados em periódicos
Repositório Institucional - UFRN Campus Universitário Lagoa NovaCEP 59078-970 Caixa postal 1524 Natal/RN - BrasilUniversidade Federal do Rio Grande do Norte© Copyright 2025. Todos os direitos reservados.
Contato+55 (84) 3342-2260 - R232Setor de Repositórios Digitaisrepositorio@bczm.ufrn.br
DSpaceIBICT
OasisBR
LAReferencia
Customizado pela CAT - BCZM